Clinical momentum Airway Therapeutics is in advanced preclinical/early clinical development for AT-100 (rhSP-D) targeting bronchopulmonary dysplasia in newborns, suggesting opportunities to engage in collaborations, contract research, or early-access partnerships with neonatal care networks and pediatric hospitals.

Leadership expansion Appointment of a new CEO with experience from CorMedix signals potential strategic realignment and fundraising activity, presenting openings for investor relations outreach, strategic partnerships, and advisory network introductions.

Awards signal validation Receiving the 2024 ATS Whitsett Award for positive Phase 1b results enhances credibility with academic centers and pharmaceutical partners, providing a talking point for co-development discussions and potential licensing or grant-supported collaborations.

Manufacturing focus Significant emphasis on developing and validating the AT-100 manufacturing process indicates a need for CMO partnerships, process development consultants, and supply chain risk assessments that could be packaged as outsourced manufacturing opportunities.

Financials and scale With modest revenue and $39M in funding, there is a clear path for collaboration with CROs for preclinical and translational studies, as well as potential licensing deals with larger biopharma companies seeking early-stage respiratory franchises.